Extracellular vesicles in urological malignancies: an update

Linxweiler, Johannes; Junker, Kerstin

doi:10.1038/s41585-019-0261-8

Cited by 92 publications

(72 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As recently reviewed, there is a broad range of studies focusing on the use of urinary miRNAs as biomarkers for BC [9,15,17]. Notably, we found only four studies on urine-derived EVs in association with BC, which reported among the others miR-21-5p [18][19][20], miR-375 [21], miR-200-family [19,20], and miR-146 [21,22] as potential diagnostic biomarkers.…”

Section: Discussionmentioning

confidence: 86%

“…In the past, the main objects of study in body fluids were free-circulating mRNAs and miRNAs especially as a diagnostic tool for BC [9]. The new challenge is to analyze the role of other sncRNAs, especially those carried in EVs, as prognostic and predictive markers [9]. In this respect, the present study focused on profiling by NGS sncRNAs contained in EVs from plasma.…”

Section: Discussionmentioning

confidence: 99%

“…In this respect, the present study focused on profiling by NGS sncRNAs contained in EVs from plasma. EVs mediate the communication between cancer cells and the microenvironment supporting the development of the tumor but also preparing pre-metastatic niche via systemic circulation to distant sites [9,13]. In BC research, urine is the most investigated body fluid because of the direct contact with the tumor tissue.…”

Section: Discussionmentioning

confidence: 99%

“…In BC research, urine is the most investigated body fluid because of the direct contact with the tumor tissue. However, studying circulating sncRNAs in other body fluids, especially in EVs, could generate better biomarkers for monitoring BC patients and for their follow up since EVs are secreted by tumor cells in the blood stream to exert an effect in distant cells [9].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

Sabo

Birolo

Naccarati

et al. 2020

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined. The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles were compared with urinary profiles from the same subjects. miR-4508 resulted downregulated in plasma EVs of muscle-invasive BC patients, compared to controls (adj-p = 0.04). In World Health Organization (WHO) grade 3 (G3) BC, miR-126-3p was upregulated both in plasma EVs and urine, when compared to controls (for both, adj-p < 0.05). Interestingly, two sncRNAs were associated with the risk class: miR-4508 with a downward trend going from controls to high risk BC, and piR-hsa-5936 with an upward trend (adj-p = 0.04 and adj-p = 0.05, respectively). Additionally, BC cases with low expression of miR-185-5p and miR-106a-5p or high expression of miR-10b-5p showed shorter survival (adj-p = 0.0013, adj-p = 0.039 and adj-p = 0.047, respectively). SncRNAs from plasma EVs could be diagnostic biomarkers for BC, especially in advanced grade.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

Sabo

Birolo

Naccarati

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…At the same time, the EV content displaying dynamic disease-specific information has a high potential even in the development of new prognostic biomarkers. EVs have been already proposed as reliable diagnostic/prognostic biomarkers in many clinical settings, such as coronary artery disease [108], renal [109], liver [110], neurodegenerative [107], and autoimmune [111] diseases, as well as in systemic sclerosis [112], in urological [113], hepatobiliary [103], and hematological [114] malignances, and in breast [115], lung [116], and ovarian cancers [117], and in cancer care [118].…”

Section: Evs As Diagnostic and Prognostic Biomarkersmentioning

confidence: 99%

Extracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers

Simeone

Bologna

Lanuti

et al. 2020

IJMS

148

117

View full text Add to dashboard Cite

Extracellular vesicles act as shuttle vectors or signal transducers that can deliver specific biological information and have progressively emerged as key regulators of organized communities of cells within multicellular organisms in health and disease. Here, we survey the evolutionary origin, general characteristics, and biological significance of extracellular vesicles as mediators of intercellular signaling, discuss the various subtypes of extracellular vesicles thus far described and the principal methodological approaches to their study, and review the role of extracellular vesicles in tumorigenesis, immunity, non-synaptic neural communication, vascular-neural communication through the blood-brain barrier, renal pathophysiology, and embryo-fetal/maternal communication through the placenta.

show abstract

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

et al. 2022

View full text Add to dashboard Cite

The prognosis of metastatic urothelial carcinoma (mUC) patients is poor, and early prediction of systemic therapy response would be valuable to improve outcome. In this exploratory study, we investigated protein profiles in sequential plasma‐isolated extracellular vesicles (EVs) from a subset of mUC patients treated within a Phase I trial with vinflunine combined with sorafenib. The isolated EVs were of exosome size and expressed exosome markers CD9, TSG101 and SYND‐1. We found, no association between EVs/ml plasma at baseline and progression‐free survival (PFS). Protein profiling of EVs, using an antibody‐based 92‐plex Proximity Extension Assay on the Oncology II ® platform, revealed a heterogeneous protein expression pattern. Qlucore bioinformatic analyses put forward a protein signature comprising of SYND‐1, TNFSF13, FGF‐BP1, TFPI‐2, GZMH, ABL1 and ERBB3 to be putatively associated with PFS. Similarly, a protein signature from EVs that related to best treatment response was found, which included FR‐alpha, TLR 3, TRAIL and FASLG. Several of the markers in the PFS or best treatment response signatures were also identified by a machine learning classification algorithm. In conclusion, protein profiling of EVs isolated from plasma of mUC patients shows a potential to identify protein signatures that may associate with PFS and/or treatment response.

show abstract

Extracellular vesicles in urological malignancies: an update

Cited by 92 publications

References 180 publications

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

Extracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

Contact Info

Product

Resources

About